Lakeland PeptidesPeptide therapy, explained · Lakeland & Polk County, FL

Peptide library

Retatrutide: What Lakeland Readers Should Know

Also known as: LY3437943, GLP-3, GLP-3 RT, triple agonist

Not reviewed by a licensed provider. Read our disclaimer

Last updated

At a glance

Type
GIP, GLP-1 and glucagon receptor agonist (triple agonist)
Human evidence
Some human trials Studied in people, but not FDA-approved for the uses it is marketed for.
FDA status
Not FDA-approved for any use; investigational. Cannot be compounded. (as of November 12, 2026)
How it is given
Injection under the skin (in clinical trials only)

Retatrutide is an experimental weight-loss drug made by Eli Lilly. It is not FDA-approved for any use as of November 2026. Products sold online as “retatrutide” or “GLP-3,” often labeled “research use only,” are not legal medicines.

What it is and how it works

Retatrutide, also called LY3437943, is a lab-made peptide (a short chain of 39 amino acids) with a fatty side chain. It is designed to be given once a week.1 It switches on three hormone receptors at once: GIP, GLP-1 and glucagon. That is why it is called a “triple agonist.”2 Semaglutide acts on one of these receptors and tirzepatide on two.

GIP and GLP-1 are gut hormones involved in appetite and blood sugar. Glucagon is a hormone that raises blood sugar. Exactly what the glucagon part adds in people was not confirmed in the sources reviewed for this page.

Online sellers sometimes call it “GLP-3” or “GLP-3 RT.”3 That is a marketing label, not a scientific drug class. In trials, it was given as a weekly injection under the skin, with the dose raised over time.42

What the research shows (and where evidence is weak)

Retatrutide has been tested in randomized controlled trials, where people are assigned by chance to the drug or a placebo (a dummy shot). Phase 3 trials are the large, late-stage studies used to seek FDA approval.

  • Phase 2 (2023). In 338 adults with obesity or overweight, the highest dose produced 24.2% average weight loss over 48 weeks, versus 2.1% on placebo.2
  • TRIUMPH-1 (phase 3, 2026). In 2,339 adults with obesity and no diabetes, average weight fell 17.6%, 23.7% and 25.0% at three dose levels over 80 weeks, versus 3.9% on placebo.4
  • TRIUMPH-2 (phase 3, 2026). In 1,152 adults with obesity and type 2 diabetes, weight fell 11.9% to 18.8%, versus 5.1% on placebo.5
  • Type 2 diabetes. In 537 adults, HbA1c (a measure of average blood sugar) fell 1.69 to 1.94 points over 40 weeks, versus 0.81 on placebo.6
  • Sleep apnea. In two trials of people with obesity and sleep apnea, breathing pauses per hour fell by about 13 to 24 more than placebo in people without diabetes, and about 9 to 15 more in people with diabetes.7
  • Knee arthritis. In two trials of people with obesity and knee pain, pain scores on a 1-to-10 scale improved by about 1.4 to 1.8 points more than with placebo.8

Where the evidence is weaker:

  • Headline numbers. News stories citing about 28% to 29% weight loss used a method that assumes everyone stayed on the drug. Counting everyone who started, as the published papers do, the top-dose figures were 25.0% (TRIUMPH-1) and 23.7% (TRIUMPH-4, a knee-arthritis trial).1
  • Who paid. Eli Lilly funded all the main trials, and several authors are Lilly employees.45
  • Very new. The phase 3 papers came out between June and November 2026. An independent review says comparisons with other drugs and long-term outcomes are still unknown.1 No head-to-head trial against tirzepatide or semaglutide was found in this research.
  • Not the online product. These results apply only to the drug made for the trials, not to vials sold online.

FDA and regulatory status

Not approved. As of November 2026, retatrutide is not FDA-approved for any use. In August 2026, Lilly said it planned to submit an application to FDA in the first quarter of 2027.9 Papers published in October and November 2026 still describe it as investigational.7 Check FDA’s announcements for any later change in status.

Cannot be compounded. FDA states that retatrutide cannot be used in compounding under federal law.10 A pharmacy-made “retatrutide” is not a legal compounded drug.

“Research use only” is not a legal loophole. On August 24, 2026, FDA sent warning letters to online peptide sellers, including one in Sarasota, Florida. The letters called their retatrutide products (“GLP-3 Reta” and “Retatrutide (GLP-3 RT)”) unapproved new drugs.113 FDA said “for research use only” labels do not count when a seller’s website shows the products are meant for people. It added that selling bacteriostatic water for mixing shows the products are meant to be injected.11 See our guides on research-chemical peptides and whether peptides are legal in Florida.

Sport. The World Anti-Doping Agency bans, at all times, any substance with no current government approval for human use, including drugs still in clinical development.12 Retatrutide is not named on the list, but it is likely covered by this ban on unapproved substances. Athletes should check with their anti-doping organization.

Common side effects and safety

In trials, stomach and bowel effects were the most common, and they rose with dose.2 Other findings:

  • Skin sensations and blood pressure. In TRIUMPH-2, abnormal skin sensations (dysesthesia) affected 4% to 7% of people versus 1% on placebo. Low blood pressure affected 1% to 6% versus under 1%.5
  • Heart rate. Heart rate rose with dose in the phase 2 trial, peaking at 24 weeks.2
  • Stopping due to side effects. In TRIUMPH-2, 12% and 8% stopped on the two higher doses, versus 5% on placebo.5
  • Serious events. In the knee-arthritis trials, serious adverse events were more common with retatrutide than with placebo.8

An independent review says stomach effects, dysesthesia, heart-rate changes and loss of lean mass all need more study.1

Products sold online carry separate risks. Their purity and strength are unknown. FDA notes that injected products bypass some of the body’s defenses against germs and toxins.11 The advocacy group Public Citizen reported 14 hospitalizations linked to retatrutide in FDA’s adverse-event database as of June 2026.13 FDA has not confirmed that count, and a report does not prove the product caused the harm.

Typical cost range

There is no legitimate price. Retatrutide is not approved, so it has no list price, no insurance coverage and no manufacturer self-pay program. Prices on “research” websites are not prices for a legal medicine, and you cannot know what those vials contain.

Outside a registered clinical trial, there is no legal source of retatrutide today. To look for open trials, search ClinicalTrials.gov for retatrutide and filter by location. If FDA approves it, prices will be set then. Our cost guide covers what drives costs for approved weight-loss medicines.

Questions to ask a provider

  • Is retatrutide right for me now, or should we look at an approved option like tirzepatide or semaglutide?
  • If you are offering retatrutide, is it through a registered clinical trial? Can I see the trial listing?
  • If someone offers me “compounded” or “research” retatrutide, what are the legal and safety risks?
  • Are there clinical trials near Lakeland that I might qualify for?
  • If it becomes approved, how would I know whether I am a good candidate?
  • I compete in sports. Who should I check with before taking any new drug?

Footnotes

  1. Mateescu DM, Capraru ID, Enache B, et al. Retatrutide as a unimolecular GIP/GLP-1/glucagon receptor tri-agonist: molecular design, pharmaceutical development and critical interpretation of emerging phase 3 evidence. Pharmaceutics. 2026;18(10):1277. https://doi.org/10.3390/pharmaceutics18101277 ↩ ↩2 ↩3 ↩4

  2. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. https://doi.org/10.1056/NEJMoa2301972 ↩ ↩2 ↩3 ↩4 ↩5

  3. U.S. Food and Drug Administration. Warning letter 735067. August 24, 2026. Accessed November 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/txp-innovations-llc-dba-tex-peptides-735067-08242026 ↩ ↩2

  4. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026;395(18):1781-1793. https://doi.org/10.1056/NEJMoa2604169 ↩ ↩2 ↩3

  5. Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. https://doi.org/10.1016/S0140-6736(26)01861-1 ↩ ↩2 ↩3 ↩4

  6. Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1). Lancet. 2026;407(10546):2402-2413. https://doi.org/10.1016/S0140-6736(26)00967-0 ↩

  7. Grunstein RR, Somers VK, Azarbarzin A, et al. Retatrutide once weekly for treatment of obstructive sleep apnea. N Engl J Med. Published online October 21, 2026. https://doi.org/10.1056/NEJMoa2611477 ↩ ↩2

  8. Schnitzer TJ, Hunter DJ, Conaghan PG, et al. Retatrutide once weekly in adults with knee osteoarthritis pain and obesity. N Engl J Med. Published online November 8, 2026. https://doi.org/10.1056/NEJMoa2610676 ↩ ↩2

  9. Eli Lilly and Company. Form 8-K exhibit: Q2 2026 sales and earnings press release. August 5, 2026. Accessed November 2026. https://www.sec.gov/Archives/edgar/data/0000059478/000005947826000077/q226lillysalesandearningsp.htm ↩

  10. U.S. Food and Drug Administration. FDA’s concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. Accessed November 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss ↩

  11. U.S. Food and Drug Administration. Warning letter 735063 (Sarasota, FL). August 24, 2026. Accessed November 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026 ↩ ↩2 ↩3

  12. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. Effective January 1, 2026. Accessed November 2026. https://www.segas.gr/wp-content/uploads/2025/11/2026list_en_final_clean_september_2025.pdf ↩

  13. Public Citizen. Hospitalizations, enforcement gaps, influencers tied to unapproved retatrutide products. News release. June 16, 2026. Accessed November 2026. https://www.citizen.org/news/hospitalizations-enforcement-gaps-influencers-tied-to-unapproved-retatrutide-products/ ↩

Frequently asked questions

Is retatrutide FDA-approved?

No. As of November 2026, retatrutide is not approved for any use. Its maker, Eli Lilly, has said it plans to apply to FDA in early 2027. Approval is not guaranteed.

Can I legally buy retatrutide online or from a clinic?

Not as a legal medicine. FDA says retatrutide cannot be used in compounding, and it has sent warning letters to sellers of 'research use only' retatrutide, calling those products unapproved new drugs. The only legal way to get it now is through a clinical trial.

Did retatrutide really cause 30% weight loss?

Headline numbers near 28% to 29% assumed everyone stayed on the drug. Counting everyone who started, the peer-reviewed figure at the highest dose was 25.0% over 80 weeks.

Is 'GLP-3' the same as retatrutide?

'GLP-3' is a marketing name some online sellers use. It is not a scientific drug class, and what is in those vials has not been checked by FDA.

Related goals

Related peptides

Questions? Talk to a licensed provider

See a free list of top rated clinics in Lakeland and Polk County, with their phone numbers and Google reviews. No one will call you.

Find a top rated provider
Find a top rated provider today